Skip To Main Content
Lilly
Menu closed
Lilly
  • Account Login / Register
  • Medical Home
    • Medical Information
  • Medical Education
  • Science
Ask Lilly

We're here to help.

Chat
Chat with us Chat with us
Question Contact Us
Expand contact lilly
Lilly

You are now leaving the Lilly Medical website

The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical

  1. Medical Information Right
  2. Diabetes Right
  3. Mounjaro (tirzepatide) injection Right
  4. How do you treat a Mounjaro® (tirzepatide) overdose?
Search Mounjaro (tirzepatide) injection (type in keywords)
Search Medical Information

If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)

Loading icon

Mounjaro ® (tirzepatide) injection

2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg

Full Prescribing Information

This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.

How do you treat a Mounjaro® (tirzepatide) overdose?

In the event of an overdosage, contact Poison Control for latest recommendations.

US_cFAQ_TZP024_OVERDOSE_T2D_CWM
US_cFAQ_TZP024_OVERDOSE_T2D_CWMen-US

See important safety information, including boxed warning, in the attached prescribing information.

Approved Dosages 

The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions.​ The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.1

After 4 weeks, increase the dosage to 5 mg once weekly.1

If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.1

The maximum dose of tirzepatide is 15 mg once weekly.1

Overdose

In the event of an overdosage, contact Poison Control for latest recommendations.1

Appropriate supportive treatment should be initiated according to the patient’s clinical signs and symptoms.1

A period of observation and treatment for these symptoms may be necessary, considering the half-life of tirzepatide is approximately 5 days.1

Enclosed Prescribing Information

MOUNJARO® (tirzepatide) injection, for subcutaneous use, Lilly

Reference

1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2024.

Date of Last Review: January 23, 2025

Are you satisfied with this content?

Can't find what you're looking for? Contact us for answers to your medical questions.

  • Copyright
  • Terms of Use
  • Privacy Statement
  • Consumer Health Privacy Notice
  • Accessibility Statement
  • Sitemap

    This site is intended for US Healthcare Professionals only.

    4.0.43 4/2025 | GLOOTH00001 04/2015 | © Lilly USA, LLC 2025. All rights reserved.

    Product names listed above are trademarks or registered trademarks owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates

    California Consumer Privacy Act (CCPA) Opt-Out Icon Your Privacy Choices
    Cookie Settings
    facebook twitter linkedin
    visit www.phactmi.org
    Lilly